神经内分泌肿瘤治疗市场规模、份额和成长分析（按肿瘤类型、治疗产品、地点、最终用途和地区）：产业预测（2025-2032）

2023年全球神经内分泌肿瘤治疗市场规模估值为23.4亿美元，从2024年的24.8亿美元成长到2032年的38.9亿美元，预测期间（2025-2032年）复合年增长率预计将达到5.8%增长率。

全球癌症发生率不断上升，特别是类癌等神经内分泌肿瘤（NET），凸显了对创新治疗的迫切需求。这些罕见的肿瘤起源于神经和内分泌系统，主要影响胃肠道，但也可见于阑尾、胰臟、直肠和肺部等器官。从胃肠道问题到心臟问题等一系列症状凸显了 NET 的复杂性。随着认知度的提高、诊断能力的提高和研发投资的增加，神经内分泌肿瘤治疗市场预计将显着成长。这一趋势表明，透过引入新的治疗方法和改进的检测方法，在预测期内将扩大解决罕见恶性肿瘤的努力。

目录

介绍

• 分析目的
• 市场范围
• 定义

分析方法

• 资讯采购
• 次要/主要资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 市场概况及展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及前景

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特分析

主要市场考虑因素

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场魅力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究

全球神经内分泌肿瘤治疗市场规模/复合年增长率：依肿瘤类型划分（2025-2032）

• 市场概况
• 脑膜瘤
• 肾上腺癌
• 类癌瘤
• 副神经节瘤
• 嗜铬细胞瘤
• 其他的

全球神经内分泌肿瘤治疗市场规模与复合年增长率：依治疗产品分类（2025-2032）

• 市场概况
• 生长抑制素类似物 (SSA)
• 标靶治疗
• 其他的

全球神经内分泌肿瘤治疗市场规模/复合年增长率：按地点划分（2025-2032）

• 市场概况
• 肺
• 胰臟
• 冒号
• 小肠
• 直肠
• 胃
• 其他的

全球神经内分泌肿瘤治疗市场规模与最终用途复合年增长率（2025-2032）

• 市场概况
• 医院
• 诊所
• 其他的

全球神经内分泌肿瘤治疗市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要企业采取的策略
• 近期市场趋势
• 主要企业市场占有率（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• 诺华公司（瑞士）
• 百时美施贵宝公司（美国）
• 辉瑞公司（美国）
• 勃林格殷格翰国际有限公司（德国）
• 和记黄埔医药有限公司（中国）
• AVEO 药厂（美国）
• 易普森製药（法国）
• 礼来公司（美国）
• Exelixis, Inc.（美国）
• Jubilant Pharmova 有限公司（印度）
• F. Hoffmann-La Roche Ltd（瑞士）
• Viatris 公司（美国）
• 赛默飞世尔科技公司（美国）
• 再生元製药公司（美国）
• 太阳製药工业有限公司（印度）
• 梯瓦製药工业股份有限公司（以色列）
• 羽扇豆（印度）
• 精确科学公司（美国）
• 高级加速器应用（法国）
• BioSynthema 公司（美国）

结论和建议

Global Neuroendocrine Tumors Treatment Market size was valued at USD 2.34 billion in 2023 and is poised to grow from USD 2.48 billion in 2024 to USD 3.89 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The global rise in cancer incidence, particularly neuroendocrine tumors (NET) such as carcinoid tumors, underscores an urgent need for innovative treatments. These rare tumors, originating from both the neurological and endocrine systems, primarily affect the gastrointestinal tract but are also found in organs like the appendix, pancreas, rectum, and lungs. Symptoms ranging from gastrointestinal issues to heart problems highlight the complexity of NETs. As awareness increases, coupled with enhanced diagnostic capabilities and rising research and development investments, the treatment market for neuroendocrine tumors is poised for significant growth. This trend is indicative of a broader commitment to addressing rare malignancies through the introduction of new therapies and improved detection methods over the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neuroendocrine Tumors Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neuroendocrine Tumors Treatment Market Segmental Analysis

Global Neuroendocrine Tumors Treatment Market is segmented by Tumor Types, Treatment Products, Sites, End Uses and region. Based on Tumor Types, the market is segmented into Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma, Pheochromocytoma and Others. Based on Treatment Products, the market is segmented into Somatostatin Analogs (SSAs), Targeted Therapy and Others. Based on Sites, the market is segmented into Lung, Pancreas, Colon, Small Intestine, Rectum, Stomach and Others. Based on End Uses, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors Treatment market is poised for growth due to the increasing incidence of neuroendocrine tumors (NET) around the world. Data from the American Society of Clinical Oncology (ASCO) indicates a steady rise in both the incidence and prevalence of these tumors, which significantly influences market dynamics. As more individuals are diagnosed with this rare condition, there is a corresponding increase in the adoption of various treatment medications, thereby further propelling market demand. This trend reflects a growing recognition of neuroendocrine tumors, leading to advancements in treatment options and an overall expansion of the market.

Restraints in the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors (NET) Treatment market faces several restraints that could limit its growth. One significant factor is the potential side effects associated with treatments, which may deter patients from pursuing therapy. Common adverse effects include elevated blood sugar levels, gallstone formation, and mild digestive issues such as bloating and nausea. Additionally, the high costs associated with developing effective treatments and pharmaceuticals can pose a substantial barrier to market expansion. As a result, these financial burdens and the apprehension surrounding treatment-related complications may impede the overall progress of the NET treatment market during the forecast period.

Market Trends of the Global Neuroendocrine Tumors Treatment Market

The global neuroendocrine tumors treatment market is witnessing a significant upward trend, primarily driven by the increasing adoption of somatostatin analogs (SSAs). As these therapeutic agents effectively inhibit tumor growth, alleviate symptoms, and improve biomarker profiles, they have emerged as the preferred choice for managing neuroendocrine tumors. Their proven safety and efficacy contribute to dominating the revenue share in the market. Additionally, ongoing clinical trials and potential approvals of newer SSAs are expected to further fuel market growth. The landscape is evolving, with rising patient awareness and advancements in treatment protocols, making it a promising arena for stakeholders in the healthcare sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Neuroendocrine Tumors Treatment Market Size by Tumor Types & CAGR (2025-2032)

• Market Overview
• Meningiomas
• Adrenal Cancer
• Carcinoid Tumors
• Paraganglioma
• Pheochromocytoma
• Others

Global Neuroendocrine Tumors Treatment Market Size by Treatment Products & CAGR (2025-2032)

• Market Overview
• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Others

Global Neuroendocrine Tumors Treatment Market Size by Sites & CAGR (2025-2032)

• Market Overview
• Lung
• Pancreas
• Colon
• Small Intestine
• Rectum
• Stomach
• Others

Global Neuroendocrine Tumors Treatment Market Size by End Uses & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Others

Global Neuroendocrine Tumors Treatment Market Size & CAGR (2025-2032)

• North America (Tumor Types, Treatment Products, Sites, End Uses)
  • US
  • Canada
• Europe (Tumor Types, Treatment Products, Sites, End Uses)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Tumor Types, Treatment Products, Sites, End Uses)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Tumor Types, Treatment Products, Sites, End Uses)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Tumor Types, Treatment Products, Sites, End Uses)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hutchison MediPharma Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AVEO Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharmova Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioSynthema Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations